Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Neurological Programs News
Neurological Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Neurological Programs. Real-time updates on events, politics, business and more.
Biogen Inc.: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis remain
Source: finanznachrichten.de
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
/PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis...
Source: prnewswire.com
Biogen Inc.: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE
Source: finanznachrichten.de
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com